Diverticulitis Market Summary

• The Diverticulitis Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• The Diverticulitis companies developing therapies include - Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Allergan (now part of AbbVie), Bayer AG, Johnson & Johnson, Pfizer Inc., Takeda Pharmaceutical Company, Eli Lilly and Company, Merck & Co., Inc., and others.

Diverticulitis Market & Epidemiology Trends

• Diverticulitis occurs when small bulging pouches in the colon, called diverticula, become inflamed, causing symptoms such as abdominal pain, fever, nausea, and changes in bowel habits. While diverticula are common with age and usually harmless (diverticulosis), inflammation can lead to serious discomfort.
• Our secondary analysis estimates that in the US, diverticulitis occurs at an incidence of approximately 188 cases per 100,000 people, with risk increasing notably with age, particularly after 50 years.
• In France, diverticulitis has a reported cumulative occurrence of approximately 3.45%, highlighting its considerable impact on the healthcare system and the need for timely diagnosis to prevent complications such as abscesses, perforation, or peritonitis.
• Mikrobiomik’s MBK-01, currently in phase II development, is emerging as a first-in-class therapeutic candidate in an area with no approved treatments, positioning it to address a significant unmet medical need. Its innovative approach has the potential to reshape the treatment landscape, attracting strong interest from the medical community and investors alike, while signaling a promising growth trajectory for this untapped market.
• The scarcity of approved drugs in this field opens a pivotal opportunity for the first targeted therapy to address a critical treatment gap and secure a dominant position in a market with strong growth potential.

DelveInsight’s comprehensive report titled “Diverticulitis Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of diverticulitis. The report presents historical and projected epidemiological data covering total incident cases of diverticulitis, gender-specific incident cases of diverticulitis, age-specific incident cases of diverticulitis, site-specific incident cases of diverticulitis and treated cases of diverticulitis. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in diverticulitis. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Diverticulitis Disease Understanding

Diverticulitis Overview

Diverticulitis is the inflammation or infection of small bulging pouches, called diverticula that form in the wall of the colon. These pouches themselves are usually harmless, but when they become inflamed, they can cause significant digestive issues. Diverticulitis is not caused by infection alone, but risk factors include aging, a low-fiber diet, chronic constipation, obesity, and certain lifestyle factors. It can occur at any age but is more common in adults over 40.

The primary symptoms of diverticulitis include sudden lower abdominal pain, often on the left side, fever, nausea, vomiting, and changes in bowel habits such as constipation or diarrhea. In severe cases, complications may develop, including abscess formation, perforation of the colon, fistula, or peritonitis, which can require urgent medical intervention or surgery.

Diverticulitis Diagnosis and Treatment Algorithm 

Diagnosing diverticulitis can be challenging due to symptom overlap with other abdominal conditions such as appendicitis, irritable bowel syndrome, or inflammatory bowel disease. Clinicians rely on a combination of clinical signs, including sudden onset of abdominal pain (often in the lower left quadrant), fever, nausea, and changes in bowel habits, along with patient history and known risk factors like age, low-fiber diet, and prior diverticular disease.

Laboratory tests, including elevated white blood cell counts and inflammatory markers like C-reactive protein (CRP), can support the diagnosis but are not specific. Imaging studies, particularly abdominal Computed Tomography (CT) scans, remain the gold standard for confirming diverticulitis, assessing severity, and detecting complications such as abscesses or perforation. Ultrasound or MRI may serve as alternatives when CT is unsuitable. Clinical scoring systems and careful evaluation of risk factors help guide testing, enabling faster, more accurate diagnosis and appropriate management decisions.

Treatment of diverticulitis focuses on controlling inflammation, managing infection, and preventing complications or recurrence. Initial therapy typically involves oral or intravenous antibiotics for mild to moderate cases, with hospitalization, bowel rest, or surgical intervention reserved for severe or complicated cases such as abscess, perforation, or peritonitis. The choice and duration of therapy depend on disease severity, patient comorbidities, and risk of recurrence. Ongoing monitoring, patient education on diet and lifestyle modifications, and timely follow-up are essential to reduce complications, detect recurrence early, and optimize long-term outcomes.

Diverticulitis Epidemiology

The epidemiology section of the diverticulitis market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the incidence of diverticulitis. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Diverticulitis Epidemiology Insights

• Based on secondary analysis, diverticulitis in the US demonstrates a gender disparity, affecting approximately 58% of females and 42% of males, highlighting a slightly higher burden among women and suggesting potential differences in risk factors, lifestyle, or disease presentation between genders.
• In France, diverticulitis shows a marked age-related pattern, with nearly 88% of cases occurring in individuals aged 60 or above, compared to 12% in those aged below 60 years old, highlighting a substantially higher burden among the elderly population.
• In Italy, diverticulitis accounts for approximately 19,000 incident cases annually, reflecting a significant clinical burden and underscoring the need for improved awareness, timely diagnosis, and effective management strategies.
• In Japan, diverticulitis demonstrates a distinct site-specific distribution, with 10.9% of cases occurring in the left colon compared to 2.8% in the right colon, reflecting a shift toward left-sided disease and suggesting potential variations in risk factors, diet, or age-related colon changes within the population.
• The epidemiology of diverticulitis is expected to change during the forecast period (2025–2034).

Diverticulitis Epidemiology Segmentation

• Total Incident Cases of Diverticulitis
• Gender-specific Incident Cases of Diverticulitis
• Age-specific Incident Cases of Diverticulitis
• Site-specific Incident Cases of Diverticulitis
• Treated Cases of Diverticulitis

Diverticulitis Market Outlook

The diverticulitis therapeutics market is further expected to increase by the major drivers, such as the rising incident population, technological advancements, and upcoming therapies in the forecast period (2025–2034).

Management of diverticulitis primarily relies on supportive care and antibiotics for mild to moderate cases, with surgical interventions reserved for complicated cases involving abscess, perforation, or peritonitis. Off-label therapies, including certain anti-inflammatory agents and probiotics, are sometimes utilized to reduce inflammation, prevent recurrence, or manage symptoms, though evidence supporting their use remains limited.

Emerging therapies like MBK-01 aim to address underlying disease mechanisms, representing a first-in-class, and targeted approach in a space with no approved drugs. By potentially reducing recurrence and complications, this novel treatments could transform the management landscape and provide alternatives for patients inadequately served by current care.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the diverticulitis market in the 7MM is expected to change significantly during the study period 2020–2034.

Diverticulitis Drug Chapters 

The drug chapter segment of the Diverticulitis report encloses a detailed analysis of Diverticulitis marketed drugs and late-stage (Phase III and Phase II) Diverticulitis pipeline drugs. It also deep dives into the Diverticulitis pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Diverticulitis Emerging Drugs

MBK-01: Mikrobiomik

MBK-01, developed by Mikrobiomik, is an oral, once-daily investigational therapy currently in Phase II development for the treatment of diverticulitis. It targets key inflammatory pathways involved in diverticular disease, aiming to reduce inflammation, prevent complications, and lower the risk of recurrence. MBK-01 represents a first-in-class, disease-modifying approach in a therapeutic area with no approved treatments, offering a potential alternative to conventional supportive care and antibiotics. Phase II results are expected in the first four months of 2026.

Note: Detailed marketed therapies assessment will be provided in the final report...

Diverticulitis Market Segmentation

DelveInsight’s ‘Diverticulitis – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future diverticulitis market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Diverticulitis Market Size by Countries

The diverticulitis market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) diverticulitis market, primarily attributed to the country’s higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Diverticulitis Market Size by Therapies

Diverticulitis Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034. 

Diverticulitis Drugs Uptake

This section focuses on the sales uptake of potential diverticulitis drugs that have recently been launched or are anticipated to be launched in the diverticulitis market between 2020 and 2034. It estimates the market penetration of diverticulitis drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the diverticulitis market.

The emerging diverticulitis therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the diverticulitis market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on diverticulitis...

Diverticulitis Market Access and Reimbursement

DelveInsight’s ‘Diverticulitis Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of diverticulitis.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views on Diverticulitis Market Report

To keep up with current diverticulitis market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the diverticulitis domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or diverticulitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the diverticulitis unmet needs.

Diverticulitis: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Harvard University, US; University of Munich, Germany; Jean Monnet University, France; University of Cagliari, Italy; Universitario Ramón y Cajal, Spain; University of Leeds, Leeds, UK; and University of Occupational and Environmental Health, Japan, among others.

As per KOLs from the US, “Diverticulitis significantly impacts patient well-being, with symptoms varying widely in intensity and presentation. Experts emphasize that emerging targeted therapies, such as MBK-01, are reshaping management by addressing underlying inflammatory pathways. Leading voices also highlight the importance of personalized approaches, given the diverse disease severity and complication risks among patients.”

As per KOLs from Germany, “Despite advances in diverticulitis management, a significant unmet need remains for effective, targeted therapies that prevent recurrence and complications without relying solely on antibiotics or surgery. Experts stress the importance of integrating multidisciplinary care, including dietary guidance, lifestyle interventions, and timely diagnostic monitoring, to better manage the broad impact of the disease on patient health and quality of life.” 

As per KOLs from Japan, “The relatively low reported incidence of diverticulitis may reflect underdiagnoses and differences in symptom recognition or reporting. Specialists highlight the need for increased awareness, early detection, and the development of targeted therapies, to address the unique clinical challenges and reduce the risk of complications in the Japanese population.”

Note: Detailed assessment of KOL Views will be provided in the full report on diverticulitis...

Diverticulitis Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the diverticulitis Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Diverticulitis Pipeline Development Activities

The Diverticulitis pipeline report offers an analysis of Diverticulitis clinical trials within Phase II and III stages and examines companies involved in developing targeted therapeutics for diverticulitis. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Diverticulitis Pipeline Development Activities

The Diverticulitis clinical trials analysis report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging diverticulitis therapies.

Scope of the Diverticulitis Market Report

• The report covers a segment of key events, an executive summary, descriptive overview of Diverticulitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along with country specific treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Diverticulitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Diverticulitis market.

Diverticulitis Market Report Insights

• Diverticulitis Patient Population
• Diverticulitis Therapeutic Approaches
• Diverticulitis Pipeline Analysis
• Diverticulitis Market Size and Trends
• Diverticulitis Market Opportunities
• Impact of Upcoming Therapies

Diverticulitis Market Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Diverticulitis Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Diverticulitis Market
• Diverticulitis Drugs Uptake

Diverticulitis Market Report Assessment

• Diverticulitis Current Treatment Practices
• Diverticulitis Unmet Needs
• Diverticulitis Pipeline Product Profiles
• Diverticulitis Market Attractiveness
• Diverticulitis Market Drivers
• Diverticulitis Market Barriers

Key Questions Answered In The Diverticulitis Market Report:

• How common is diverticulitis?
• What are the key findings of diverticulitis epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for diverticulitis?
• What are the disease risk, burden, and unmet needs of diverticulitis?
• At what CAGR is the diverticulitis market and its epidemiology is expected to grow in the 7MM during the forecast period (2025–2034)?
• How would the unmet needs impact the diverticulitis market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of diverticulitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025–2034)?
• How many companies are currently developing therapies for the treatment of diverticulitis?

Reasons to buy Diverticulitis Market Forecast Report

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the diverticulitis Market.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.